loading page

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
  • +12
  • Shinya Yamamoto,
  • Kei Kawashima,
  • Yoshie Fujiwara,
  • Shoko Adachi,
  • Kazutaka Narui,
  • Chiaki Hosaka,
  • Rina Takahashi,
  • Sho Tsuyuki,
  • Makoto Sugimori,
  • Miki Tanoshima,
  • Mahato Sasamoto,
  • Masanori Oshi,
  • Akimitsu Yamada,
  • Chikara Kunisaki,
  • Itaru Endo
Shinya Yamamoto
Yokohama City University Medical Center

Corresponding Author:[email protected]

Author Profile
Kei Kawashima
Yokohama City University Medical Center
Author Profile
Yoshie Fujiwara
Yokohama City University Medical Center
Author Profile
Shoko Adachi
Yokohama City University Medical Center
Author Profile
Kazutaka Narui
Yokohama City University Medical Center
Author Profile
Chiaki Hosaka
Yokohama City University Medical Center
Author Profile
Rina Takahashi
Yokohama City University Medical Center
Author Profile
Sho Tsuyuki
Yokohama City University Medical Center
Author Profile
Makoto Sugimori
Yokohama City University Medical Center
Author Profile
Miki Tanoshima
Yokohama City University Medical Center
Author Profile
Mahato Sasamoto
Yokohama City University School of Medicine Graduate School of Medicine
Author Profile
Masanori Oshi
Yokohama City University School of Medicine Graduate School of Medicine
Author Profile
Akimitsu Yamada
Yokohama City University School of Medicine Graduate School of Medicine
Author Profile
Chikara Kunisaki
Yokohama City University Medical Center
Author Profile
Itaru Endo
Yokohama City University School of Medicine Graduate School of Medicine
Author Profile

Abstract

A 34-year-old woman with breast cancer and the BRCA2: p.Gln3047Ter was treated with olaparib. After tumor progression, cancer genomic profiling testing revealed the BRCA2 p.Gln3047Ter and p.Gln3047Tyr, with 48.9% and 0.37% allele frequency, respectively. These findings shed light on reversion mutation as a resistance mechanism to olaparib in breast cancer.
19 Feb 2023Submitted to Clinical Case Reports
20 Feb 2023Submission Checks Completed
20 Feb 2023Assigned to Editor
22 Feb 2023Reviewer(s) Assigned
16 Mar 2023Review(s) Completed, Editorial Evaluation Pending
16 Mar 2023Editorial Decision: Revise Minor
07 May 20231st Revision Received
10 May 2023Submission Checks Completed
10 May 2023Assigned to Editor
10 May 2023Review(s) Completed, Editorial Evaluation Pending
30 May 2023Editorial Decision: Accept